
    
      A double-blind, randomized, placebo controlled, parallel group study of eszopiclone in
      elderly subjects with primary chronic insomnia. The study will involve up to 9 visits and
      subject participation will be approximately 18 weeks. This study was previously posted by
      Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and
      in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    
  